Results and discussion
To identify CARD-containing proteins, we screened public databases using a generalized profile [6] constructed from all currently known CARD sequences [5] . An expressed sequence tag clone (EST clone 799136) containing a CARD was identified (GenBank accession AF064824) and corresponded to a protein of 540 amino acids with an estimated molecular mass of 62 kDa and an overall structural organization similar to RIP (Figure 1a) . The amino-terminal region (amino acids 18-294) contains a predicted serine/threonine kinase domain which is most homologous to the kinase domain of RIP (28% sequence identity), whereas the carboxyl terminus (amino acids 435-523) contains a CARD motif instead of the structurally related DD found in RIP. The intermediate region (amino acids 295-434) shows no significant homology to any presently known protein. By northern blot analysis (see Supplementary material published with this paper on the internet), CARDIAK was found to be expressed in several human tissues and cell lines, with two transcript sizes of approximately 1.9 kb and 2.5 kb. Highest expression was found in placenta, pancreas and peripheral blood leukocytes (PBLs). The transformed B-cell line Raji also expressed high levels of CARDIAK mRNA, suggesting that the strong signal in PBLs may be derived from B lymphocytes.
We next tested the predicted serine/threonine kinase activity of CARDIAK in an in vitro kinase assay. SDS-PAGE analysis revealed a 32 P-labeled 65-68 kDa band, indicating that CARDIAK is a protein kinase that undergoes autophosphorylation. The kinase activity was lost when Asp146, an invariant residue found in all protein kinases and shown to be essential for the enzymatic activity of the c-Kit kinase [7, 8] , was mutated to Asn (CARDIAK(D146N), Figure 1b ).
We next assessed effector functions that had been described for RIP -the induction of apoptosis and the activation of NF-κB and JNK [1, 8, 9] . Whereas overexpression of TRADD and RIP in 293T cells led to extensive cell death, cells overexpressing CARDIAK did not display characteristic features of apoptosis (data not shown). Coexpression of CARDIAK with JNK in 293T cells potently induced JNK activation compared with the activity resulting from coexpression with the vector control ( Figure 2a ). It is unlikely that CARDIAK directly activated JNK by phosphorylation, as the kinase-defective CARDIAK(D146N) activated JNK as potently as the wild-type kinase. A CARDIAK construct containing the kinase and intermediate domain (amino acids 7-425) failed to activate JNK, whereas weak but reproducible JNK activation was observed with a construct containing the CARD motif alone (amino acids 431-540).
As RIP-deficient mice have an impaired NF-κB signaling pathway [3] , we investigated whether CARDIAK was able to activate NF-κB using a luciferase reporter gene driven by NF-κB-binding sites. Expression of CARDIAK in Figure 1 Structure and enzymatic activity of CARDIAK. (a) Predicted amino acid sequence of human CARDIAK, which contains a kinase domain and a CARD motif linked by a connecting region of approximately 140 amino acids. The kinase domain of CARDIAK is aligned with the kinase domain of human RIP (GenBank accession U50062), and the CARD motif is aligned with the CARD motifs of the equine herpes virus-2 E10 protein, RAIDD, caspase-1, caspase-2, caspase-9, c-IAP1 and APAF-1 [5] . Black boxes indicate greater than 50% amino acid sequence identity and gray shading indicates greater than 50% sequence similarity through conservative amino acid substitutions. The amino acid position mutated to generate a kinase-inactive CARDIAK (D146N), is marked by a star. (b) Kinase activity of CARDIAK. Lysates from 293T cells expressing vesicular stomatitis virus (VSV)-tagged wild-type CARDIAK or kinase-defective CARDIAK(D146N) and from control transfectants were subjected to immunoprecipitation and in vitro kinase assay [13] followed by SDS-PAGE and western blotting, and the membrane was subjected to autoradiography (upper panel, CARDIAK-P) or immunoblot analysis with anti-VSV antibody (P5D4, Sigma; lower panel). Numbers on the left refer to marker sizes in kDa. were cotransfected with 1 µg NF-κB luciferase reporter plasmid (pNF-κBluc), 0.5 µg pCMV β-gal (as an internal transfection efficiency control), the indicated CARDIAK constructs and, where indicated, with a dominant negative TRAF2 construct (TRAF2-DN), and empty vector to give 6 µg total DNA. Luciferase activities were determined as previously described [14] . Values shown are averages for representative experiments in which each transfection was carried out in duplicate.
293T cells indeed resulted in a dose-dependent activation of the reporter gene, reaching an almost 35-fold increase in luciferase activity compared with the control vector ( Figure 2b ). As was found with JNK, the activation of NF-κB was independent of CARDIAK kinase activity. CARDIAK constructs encompassing the intermediate domain with the wild-type or the inactive kinase domain failed to activate NF-κB, whereas the CARD-containing carboxyl terminus weakly induced NF-κB activation (Figure 2c ).
The TNFR family members can activate NF-κB by recruiting specific members of the TRAF family, two of which, TRAF1 and TRAF2, were initially identified as components of the TNFR-2 signaling complex [9] . Expression of a dominant-negative form of TRAF2 in 293T cells blocked NF-κB activation induced by CARDIAK (Figure 2c ), but not JNK activation induced by CARDIAK (data not shown), indicating that CARDIAK may act upstream of TRAF2 in ΝF-κΒ activation induced by one of the TNFR family members. As both TRAF1 and TRAF2 have been shown to bind to RIP [10] , we investigated whether TRAF1 and TRAF2 physically interacted with CARDIAK. Tagged versions of CARDIAK and either TRAF1 or TRAF2 were transiently expressed in 293T cells. Subsequent immunoprecipitation revealed that both TRAF1 and TRAF2 proteins associated with CARDIAK (Figure 3a,b) .
We also searched for possible CARD-containing binding partners of CARDIAK. Several different FLAG-tagged
Brief Communication 887 were cotransfected with the indicated expression vectors, and anti-FLAG immunoprecipitates (IP) were prepared and analysed [15] for coprecipitating molecules by immunoblotting using anti-VSV and anti-AU-1(a 6 amino acid epitope of the bovine papilloma virus capsid protein) antibodies (BAbCO), respectively. For (a-e), the expression levels of the transfected proteins in the cell extracts are shown in the lower panels. (c) Interaction of CARDIAK with c-IAPs. Expression vectors for hemagglutinin (HA)-tagged CARDIAK and for FLAGtagged c-IAP1 and c-IAP2 were cotransfected into 293T cells as indicated, and anti-FLAG immunoprecipitates were analysed for the presence of CARDIAK by immunoblotting using anti-HA antibody (HA.11, BAbCO). The coimmunoprecipitation protocol used for the analysis of c-IAP binding to CARDIAK has been described elsewhere [4] . (d,e) Interaction of CARDIAK with caspase-1. Cells (293T) were transfected, as indicated, with expression vectors for VSV-tagged CARDIAK and for FLAG-tagged caspase-1, caspase-2 (Ich1 s ), caspase-4, caspase-9, RAIDD and E10 of equine herpes virus-2. FLAG-tagged full-length (FL) caspase-1 or its CARD region (amino acids 2-92) were used in (e). The caspase inhibitor zVAD-fmk (50 µM) was added after transfection for the experiment shown in (d) to prevent the cytotoxic effects of caspase overexpression. Anti-FLAG immunoprecipitates were prepared and analysed [15] for the presence of CARDIAK by immunoblotting using anti-VSV antibody. A shorter exposure is shown for the lower part of of the anti-FLAG western blot in (e). (f) Activation of pro-caspase-1 by CARDIAK. Cells (293T) were cotransfected with expression vectors for the full-length, carboxyterminally FLAG-tagged caspase-1 (5 µg) and either 3 µg or 0.3 µg of wt or mutated (D146N) CARDIAK, as indicated. Cell extracts were analysed 24 h after transfection for the presence of FLAG-caspase-1 (upper panel) or of the p20 active subunit of caspase-1 (lower panel) by immunoblotting using anti-FLAG or anti-p20 antibodies (a gift of J. Yuan), respectively. In (a-f), protein sizes in kDa are shown to the left of the blots.
CARD-containing proteins [5] were expressed in 293T cells and assayed for their ability to interact with coexpressed CARDIAK. We found that cellular inhibitor of apoptosis protein 1 (c-IAP1) and to a lesser extent, c-IAP2 which together with TRAF1 and TRAF2 both form part of the TNFR-2 signaling complex [11] , coprecipitated a small amount of CARDIAK (Figure 3c ). As truncated c-IAPs containing only the CARD region did not interact with CARDIAK (data not shown), it is likely that the weak CARDIAK-c-IAP interaction is indirect, potentially mediated by TRAF1 and/or TRAF2. In contrast, a strong interaction between CARDIAK and caspase-1 was detected, whereas other CARD-containing proteins (caspase-2, caspase-4, caspase-9, RAIDD and the viral protein E10) were unable to coprecipitate CARDIAK (Figure 3d) . The association between CARDIAK and caspase-1 was mediated by the CARD motifs in the two molecules, as a truncated caspase-1 molecule containing only the CARD motif (amino acids 2-92) could interact with CARDIAK (Figure 3e) , and a CARDIAK construct lacking the CARD did not coprecipitate with caspase-1 (data not shown). Moreover, expression of CARDIAK together with caspase-1 led to the processing of caspase-1, resulting in the formation of the p20 active subunit of caspase-1 (Figure 3f ). The activation of caspase-1 by CARDIAK correlated with the amount of cotransfected CARDIAK. It did not require the kinase activity of CARDIAK, and it could be inhibited by coexpression of the CARD of CARDIAK (Figure 3f and data not shown).
In summary, we have identified a RIP-like serine/threonine kinase, CARDIAK, which may be implicated in the regulation of signaling pathways initiated by TNFR family members. CARDIAK overexpression leads to JNK and NF-κB activation, and the observed ΝF-κΒ activation correlates with a physical and functional interaction of CARDIAK with TRAF2. CARDIAK appears to bind directly to the CARD-containing pro-domain of caspase-1, and coexpression of CARDIAK with pro-caspase-1 correlates with the formation of active caspase-1. Little is known about the molecular mechanism that leads to caspase-1 activation, but it is likely to involve the recruitment of pro-caspase-1, through its CARD motif, by one of the TNFR family members. Indeed, stimulation of CD40 has been shown to activate caspase-1 in vascular smooth muscle and endothelial cells with the subsequent release of the active proinflammatory IL-1β [12] . Although the physiological function of CARDIAK is not known as yet, ongoing studies aim to assess the precise role of CARDIAK in the NF-kB and JNK pathways, as well as the potential effect of CARDIAK on caspase-1 activation and inflammation.
Supplementary material
A figure showing CARDIAK mRNA expression in various human tissues and cell lines, and details of the expression vectors used in this study are published with this paper on the internet. 
Material and methods

Expression vectors
The following CARD-containing proteins or protein fragments were amplified using Pwo polymerase (Boehringer) by standard PCR methods with the indicated specific primers with suitable restriction sites on 5′ and 3′ ends, on cDNA templates from the indicated sources: full-length human CARDIAK (amino acids 2-540) and the carboxy-terminal CARD of CARDIAK (amino acids 431-540) were amplified using oligos JT676 (5′ AACGGGGAGGCCATCT-GCAGCG 3′) and JT677 (5′ CTCGAGCAGTCACTTACATGCTTT-TATT 3′) and oligos JT848 (5′ CTGCAGCCTGGTATAGCCCAG 3′) and JT677, respectively, on EST clone 799136; E10 of EHV-2 (amino acids 2-311) was amplified using oligos JT672 (5′ CTGCAGCCTGGTATAGCCCAG 3′) and JT673 (5′ CTCGAGTT-TAGCAGCAGAAAAACCTCC 3′) on viral EHV-2 DNA (a gift of A.J. Davison). The CARD region of human caspase-1 (amino acids 2-92) was amplified using oligos JT846 (5′ CTGCAGAGCCGACAAGGTC-CTGAAG 3′)and JT847 (5′ GCGGCCGCTAATCTGCTGAGAGTC-CCAG 3′), full-length human caspase-2 (Ich-1 S ) using oligos JT633 (5′ CGGAATTCATGCATCCTCATCATCAG 3′) and JT634 (5′ GCTCTAGATCATAGAGCAAGAGAGGC 3′) and caspase-9 using oligos JT842 (5′ GACGAAGCGGATCGGCGGCTC 3′) and JT849 (5′ TTATGATGTTTTAAAGAAAAGTTT 3′: the cDNAs for human caspase-1, 2 and 9 were a gift of C.J. Froelich. Full-length human caspase-4 was amplified using oligos JT840 (5′ CTGCAGAGCA-GAAGGCAACCACAGA 3′) and JT1054 (5′ GTCGA-CATTGCCAGGAAAGAGGTAG 3′: the cDNA was a gift of J. Yuan, c-IAP1 and c-IAP2 were amplified using oligos JT612 (5′ CGGAATTCATGCACAAAACTGCCTC 3′) and JT613 (5′ TCTCC-CGGGTTAAGAGAGAAATGTACG 3′), and using oligos JT614 (5′ CGGAATTCATGAACATAGTAGAAAAC 3′) and JT615 (5′ GCTC-TAGATCATGAAAGAAATGTACG 3′), respectively: the cDNA was kindly provided by D. Goeddel.
Mutation of the kinase domain of CARDIAK (Asp146 to Asn, D146N) was achieved by site-directed mutagenesis with two sequential rounds of PCR, using oligos JT676 and JT677 (see above) in combination with JT924 (5′ CATCATAATTTAAAGACTCAGAATATC 3′) and JT925 (5′ GAGTCTTTAAATTATGATGAAGTAA 3′) which altered Asp146 to Asn and introduced a silent mutation creating a DraI site for screening of the cloned mutated PCR product.
PCR products were cloned into pCRblunt (Invitrogen), followed by subcloning into derivatives of pCR3 (Invitrogen), in frame with a carboxy-terminal FLAG tag (caspase-4) or with an amino-terminal FLAG tag, VSV tag or HA tag (all others).
Human RAIDD was amplified with Taq polymerase (GIBCO) using oligos JT595 (5′ AATGGAGGCGCAGAGACAAAC 3′) and JT596 (5′ AGCGGTTGCTGGAGGCACC 3′) on EST clone 140648; the PCR product was cloned into pCR2.1 (Invitrogen) and subcloned, using the EcoRI sites in the vector, into a pCR3-derived expression vector, in frame with an amino-terminal FLAG tag.
All above described cloned PCR products were checked by sequencing to ensure that no errors had been introduced by PCR.
Constructs containing the kinase domain (wild-type or mutated) and the intermediate domain of CARDIAK were obtained by subcloning of a PstI fragment (nucleotides 22-1275) of the wild-type or the mutated CARDIAK cDNA into a pCR3-derived expression vector, in-frame with an amino-terminal VSV tag.
The following expression plasmids were obtained from the indicated sources: NF-κBluc (V. Jongeneel); FLAG-JNK (C. Widmann); GFP-hTRAF2 (amino acids 87-501) and FLAG-tagged mTRAF1 (H. Wajant); AU1-tagged hTRAF2 (H. Engelmann); and carboxy-terminally FLAG-tagged caspase-1 (J. Yuan).
Supplementary material Figure S1
Northern blot showing the tissue distribution of CARDIAK transcripts. Northern blots of various human tissues and tumor cell lines (Clontech) were hybridized with a 32 P-labeled cDNA probe that hybridizes to the kinase and the intermediate domain of human CARDIAK (a PstI fragment corresponding to nucleotides 22-1275) and the blots were subsequently hybridized with β-actin. β-actin S p l e e n T h y m u s P r o s t a t e H e a r t B r a i n P l a c e n t a L u n g L i v e r K i d n e y P a n c r e a s T e s t i s O v a r y S m a l l i n t e s t i n e C o l o n P B L S k e l e t a l m 
